Skip to content
OpenCapital
Get started

Intellia Therapeutics NTLA Increase (decrease) in contract liabilities and current deferred income

Increase (decrease) in contract liabilities and current deferred income at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$20.82M-51.8%
ALN
Alnylam PharmaceuticalsALNY
——

Other financials

Income statement

See full
Revenue$15.0M-9.5%
Operating income-$100.5M+16.8%
Net income-$96.2M+15.8%
EPS (diluted)-$0.81+26.4%

Balance sheet

See full
Cash & equivalents$134.7M+6.2%
Total debt$80.5M-32.5%
Total equity$620.9M-20.4%
Total assets$758.8M-23.1%

Cash flow

See full
Operating cash flow-$117.3M+21.2%
CapEx$79.0K-89.3%
Free cash flow-$117.4M+21.5%

Valuation

See full
Market cap$2.17B+106%
Enterprise value$2.11B+100%
P/S32.8×+9.7×

Profitability

See full
Operating margin-636.6%-202pp
Net margin-597%-194pp
FCF margin-550.2%-140pp

Returns & leverage

See full
Return on equity-56.3%-1.5pp
Debt / equity0.1×0.0×
Current ratio6.1×+1.2×

Where this comes from

Reported directly by Intellia Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Intellia Therapeutics's increase (decrease) in contract liabilities and current deferred income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Intellia Therapeutics's increase (decrease) in contract liabilities and current deferred income?
Intellia Therapeutics (NTLA) reported increase (decrease) in contract liabilities and current deferred income of -$6.66M in Q1 2026.
How has Intellia Therapeutics's increase (decrease) in contract liabilities and current deferred income changed year-over-year?
Intellia Therapeutics's increase (decrease) in contract liabilities and current deferred income decreased by 30.7% year-over-year, from -$5.1M to -$6.66M.
What is the long-term trend for Intellia Therapeutics's increase (decrease) in contract liabilities and current deferred income?
Over 3 years (2021 to 2025), Intellia Therapeutics's increase (decrease) in contract liabilities and current deferred income has grown at a -3.6% compound annual growth rate (CAGR), from -$31.36M to -$28.11M.